Questions about this technology? Ask a Technology Manager
Download Printable PDF
North Carolina State University is seeking a commercial licensee to commercialize a platelet membrane- coated nonparticulate platform for the enhance treatment of multiple myeloma and thrombus.Abstract
Multiple Myeloma is one of the most frequently occurred hematological cancers. Although there has been significant advances radiation therapy chemotherapy and stem cell implantation, the treatment of MM remains a challenge. The non-specific distribution and short circulation time after proteasome inhibitor combination regimens sometimes results in side effects and has limitations in application. In addition, there is very often the emergence of thrombus. Therefore, there is a need for a new delivery mechanism for proteasome inhibitors such as bortezomib.
Researchers at North Carolina State University have developed a platelet membrane coated nanoparticulate platform for the targeted delved of bortezomib at the myeloma site. A core-shell structured nanocarrier with a platelet membrane wrapped in the surface transports the bortezomib and tPA to the desired location. After intravenous injection, the nanoparticles accumulate at the myeloma site through sequential targeting of the bone microenvironment.Advantages